Abstract 1541
Background
Metastatic Leydig cells tumours (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed LDLR-TERT gene fusion upon routine genetic profiling for detection of therapeutic targets, which was then followed by an investigation into a cohort of additional LCT.
Methods
20 LCT (7 metastatic and 13 primary tumours) from 3 participating institutions (Caris Life Sciences, Phoenix, USA; Clinical Hospital Center, Zagreb, Croatia and Biopticka Laborator, Plzen, Czech Republic) were analyzed using massively parallel DNA and RNA sequencing (NGS) approach. Immunohistochemistry (IHC) was used for detection of selected protein biomarkers.
Results
TERT gene fusions were detected only in metastatic Leydig cell tumours, in three of 5 successfully analyzed cases (RMST:TERT, LDLR:TERT and B4GALT5:TERT, respectively). The case with B4GALT5:TERT fusion also showed amplifications (>6 copies) of TOP1 and CCND3 genes. TP53 mutation (M246I) was detected in one metastatic tumour without TERT fusion. No gene fusions were found in any primary tumours (0/8 successfully analyzed). 3/6 primary tumours showed multiple gene amplifications, without a consistent pattern. At the protein level (IHC) 5/7 metastatic and 6/7 primary tumours over-expressed TOP1. Full length androgen receptor (AR) was overexpressed in 7/8 primary tumours (without detectable ARv7 mRNA or ARv7 protein), but only in 1 of 5 metastatic LCT. No tumours exhibited high tumour mutational burden, microsatellite instability nor expressed PD-L1 in tumour cells.
Conclusions
Our study for the first time identified TERT gene fusions as a main/sole detected genetic alteration and a potential therapeutic target in malignant, metastatic Leydig cell tumours. Additional biomarkers (TOP1 amplification and over-expression) may help guide decisions on chemotherapy for selected individual patients. Androgen receptor blockade may be considered in AR overexpressing tumours without evidence of ARv7 presence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Caris Life Sciences.
Funding
Caris Life Sciences.
Disclosure
Z. Gatalica: Leadership role: Caris Life Sciences. J. Xiu: Leadership role, employment: Caris Life Sciences. J. Swensen: Leadership role, employment: Caris Life Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract